NCT06060717

Brief Summary

The purpose of this clinical investigation is to evaluate the performance and safety of the F\&P Caramel nasal mask in a home environment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 24, 2023

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 29, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

November 27, 2023

Completed
14 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 11, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 11, 2024

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

September 23, 2025

Completed
Last Updated

September 23, 2025

Status Verified

September 1, 2025

Enrollment Period

14 days

First QC Date

September 24, 2023

Results QC Date

August 17, 2025

Last Update Submit

September 3, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Therapeutic Efficacy

    Determined by Apnea-Hypopnea Index (AHI) recorded on PAP therapy machines after 14 days of use. The Apnea-Hypopnea index (AHI) is the sum of the apneas and hypopneas divided by the hours of sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and \>= 30/h = severe AHI is measured by dividing the total number of recorded apneas (complete breathing stops) and hypopneas (shallow breathing episodes) by the total number of hours a person slept during an overnight sleep study or using a PAP device. Higher AHI values represent worse outcomes. There is no maximum theoretical index score.

    Baseline and14±5 days

  • Epworth Sleepiness Scale

    All relevant time points used in the calculation in the Time Frame (e.g., baseline and 14±5 days). Note: change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 14±5 days minus value at baseline). Change between two time points is reported. Scale range: 0 (minimum score) to 24 (maximum score) (higher scores represent worse outcomes)

    Baseline and14±5 days

Study Arms (1)

Single-arm, non-randomised open-label

OTHER
Device: F&P Caramel

Interventions

Nasal mask

Single-arm, non-randomised open-label

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Persons who are ≥22 years of age
  • Persons who weigh ≥66 pounds
  • Persons who have been prescribed PAP therapy by a physician
  • Persons who are existing nasal mask or sub-nasal mask users with ≥3 months of use prior to enrolment in the clinical trial
  • Persons who are compliant with PAP therapy for ≥4 hours per night for ≥70% of nights for a 14-day period within 30 days prior to enrolment in the clinical trial
  • Persons who are fluent in spoken and written English
  • Persons who possess the capacity to provide informed consent

You may not qualify if:

  • Persons who are intolerant to PAP therapy
  • Persons who possess, or suffer from, anatomical or physiological conditions which make PAP therapy inappropriate
  • Persons who are required to use PAP therapy for \>12 hours per day or for extensive periods, not including sleep or naps
  • Persons who are trying to get pregnant, are pregnant, or think they may be pregnant
  • Persons who have an IPAP pressure of \>30 cmH2O if on BPAP
  • Persons who use a PAP therapy device for the delivery of medicines, except supplemental oxygen
  • Persons who use a PAP therapy device that does not possess data recording capabilities to capture AHI and a numerical indicator of leak that is accessible to the investigation site

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clayton Sleep Institute

St Louis, Missouri, 63123, United States

Location

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Results Point of Contact

Title
Kelly Tay
Organization
Fisher & Paykel Healthcare Ltd

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 24, 2023

First Posted

September 29, 2023

Study Start

November 27, 2023

Primary Completion

December 11, 2023

Study Completion

June 11, 2024

Last Updated

September 23, 2025

Results First Posted

September 23, 2025

Record last verified: 2025-09

Locations